1. Home
  2. BNR vs DHY Comparison

BNR vs DHY Comparison

Compare BNR & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$8.62

Market Cap

179.7M

Sector

Health Care

ML Signal

HOLD

DHY

Credit Suisse High Yield Bond Fund

HOLD

Current Price

$1.75

Market Cap

184.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNR
DHY
Founded
2014
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Medical Specialities
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
179.7M
184.4M
IPO Year
2019
1998

Fundamental Metrics

Financial Performance
Metric
BNR
DHY
Price
$8.62
$1.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.5K
563.9K
Earning Date
06-05-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$111.65
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.06
$1.73
52 Week High
$41.72
$2.16

Technical Indicators

Market Signals
Indicator
BNR
DHY
Relative Strength Index (RSI) 28.99 40.26
Support Level $8.04 N/A
Resistance Level $9.70 $2.05
Average True Range (ATR) 1.17 0.01
MACD -0.06 0.00
Stochastic Oscillator 7.02 25.00

Price Performance

Historical Comparison
BNR
DHY

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

About DHY Credit Suisse High Yield Bond Fund

Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.

Share on Social Networks: